RankAlpha logo
Back to Rankings

AUPH

AuriniaB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings bull case is that Aurinia is still showing clean LUPKYNIS growth, strong profitability, positive operating cash flow, and enough balance-sheet capacity to pursue buybacks and pipeline expansion at the same time. The Kezar transaction also creates a second leg of optionality beyond the legacy single-product story.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
2026 guidance was reiterated, not raised, which can disappoint after a strong run and makes the quarter look more like steady execution than acceleration.
Momentum
48
Value
65
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $19.00 · Bear $13.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum48 · Δ7d -6.2
Value65 · Δ7d +0.2
Sentiment57 · Δ7d +2.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
-13.5
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.8
Sentiment
57
33% active weight
Current posture
7d trendImproving
Δ7d
+2.5
Δ21d
+13.5
Why this grade

Composite grade B. Momentum 47.6 / Value 65.3 / Sentiment 56.8

Fundamentals (TTM)
As of 2026-05-29
Market Cap
$1.97B
Beta
1.52
Shares Out
131.84M
P/E (TTM)
27.3
P/S (TTM)
7.59
P/FCF (TTM)
16.83
Rev YoY
+8.4%
EPS YoY
+135.5%
Gross Margin
+88.9%
Op Margin
+26.3%
Net Debt
-$285.84M
Current Ratio
5.76
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology